- Tonix Pharmaceuticals (NASDAQ:TNXP) has added ~14.6% in the post-market after the company said in a regulatory filing that plans are underway to construct a commercial-scale manufacturing site to develop and manufacture vaccines including its experimental COVID-19 shot, TNX-1800.
- The Montana facility intended to develop and manufacture Tonix’s vaccine candidates will be a “public/private sector collaboration between Ravalli County and Tonix Pharmaceuticals that will bring more high-tech bioscience jobs to the Bitterroot Valley,” the company said.
- “One of the things that the COVID-19 pandemic exposed was major shortcomings in U.S. domestic vaccine development and manufacturing capabilities,” Tonix CEO Seth Lederman noted, adding that the company “is striving to be a pioneer in American made vaccine development and production.
- Early this week, Tonix announced its plans to develop the fibromyalgia candidate, TNX-102 SL, as a potential treatment for Long COVID Syndrome.
- The company has also formed licensing agreement with OyaGen for TNX-3500 an antiviral inhibitor of SARS-CoV-2 currently undergoing studies as a treatment of COVID-19 and potentially other viral disorders.